VIR

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 6

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 877,135

F4 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 5

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 61,660

F3 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

SEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 4

SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F2 · ownership.nature: On August 30, 2018, the reporting person contributed 1,907,329 shares of the Issuer's common stock to the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "Trust"), a grantor retained annuity trust for the benefit of himself and his children. Upon termination of the Trust, an aggregate of 1,877,590 of the shares were transferred to trusts for the benefit of each of his daughters, of which he and his spouse serve as trustees. The remaining 29,739 shares were distributed to the reporting person.

SEC source: 0001209191-21-054577 · doc4.xml · derivative · entry 5

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,591

Underlying: Common Stock · 5,000 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 4

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.295 to $50.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.28 to $49.775 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,389

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.16 to $49.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-054577 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-054096 · doc4.xml · derivative · entry 3

Napolitano Janet · CIK 0001821008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,565

Underlying: Common Stock · 1,435 shares

Expires 2030-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/3 of the shares subject to the stock option vested and became exercisable on August 28, 2021, and the remaining shares vest in 24 equal monthly installments thereafter.

SEC source: 0001209191-21-054096 · doc4.xml · nonDerivative · entry 2

Napolitano Janet · CIK 0001821008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,374

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-054096 · doc4.xml · nonDerivative · entry 1

Napolitano Janet · CIK 0001821008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-053560 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,380

Underlying: Common Stock · 2,750 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-053560 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

SEC source: 0001209191-21-053560 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-053331 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,130

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-053331 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-053331 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-053237 · doc4.xml · derivative · entry 3

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,441

Underlying: Common Stock · 10,000 shares

Expires 2029-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on September 15, 2020, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-053237 · doc4.xml · nonDerivative · entry 2

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

SEC source: 0001209191-21-053237 · doc4.xml · nonDerivative · entry 1

Rice Steven J. · CIK 0001820108 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-053236 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,505

Underlying: Common Stock · 13,750 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-053236 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-053236 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-052964 · doc4.xml · nonDerivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,611,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.10 to $45.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-052964 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,620,833

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-052790 · doc4.xml · derivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,591

Underlying: Common Stock · 5,000 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-052790 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-052790 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-050905 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,255

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-050905 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-050905 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-050065 · doc4.xml · derivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,129

Underlying: Common Stock · 5,000 shares

Expires 2029-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-050065 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.61 to $35.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-050065 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 3

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,030

F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.22 to $37.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-049147 · doc4.xml · nonDerivative · entry 2

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,378

F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $37.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-048466 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,630

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-048466 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-048466 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-047978 · doc4.xml · derivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,982

Underlying: Common Stock · 4,630 shares

Expires 2028-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-047978 · doc4.xml · nonDerivative · entry 2

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.12 to $37.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-047978 · doc4.xml · nonDerivative · entry 1

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,907

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-047505 · doc4.xml · nonDerivative · entry 2

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,626,962

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $38.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-047505 · doc4.xml · nonDerivative · entry 1

SATO VICKI L · CIK 0001197020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,633,325

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.11 to $37.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-047285 · doc4.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,029

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.18 to $36.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-21-046688 · doc4.xml · derivative · entry 3

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,005

Underlying: Common Stock · 1,375 shares

Expires 2028-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-046688 · doc4.xml · nonDerivative · entry 2

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,700

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.

SEC source: 0001209191-21-046688 · doc4.xml · nonDerivative · entry 1

Virgin Herbert · CIK 0001786378 · EVP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046012 · doc4.xml · derivative · entry 4

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,129

Underlying: Common Stock · 5,000 shares

Expires 2029-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-21-046012 · doc4.xml · nonDerivative · entry 3

Pang Phillip · CIK 0001787370 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.60 to $41.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.